What the FDA decided on Apitegromab for Spinal muscular atrophy
The FDA approved Apitegromab (Isembyld) for spinal muscular atrophy (SMA).
Approved 19 days ahead of its September 30th action date as the first muscle-targeted treatment for SMA. The label requires patients to already be on an SMN2-targeted therapy, making it an add-on rather than a replacement.
Who the Apitegromab decision matters to
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing progressive muscle weakness and atrophy. The condition results from deficiency of SMN (survival motor neuron) protein.
Gene therapy and antisense drugs have transformed SMA outcomes since 2016, and a first muscle-targeted add-on was approved in 2026.
Prevalence: 1 in 10,000 to 14,000 births; 1 in 25 people are carriers. See our full Spinal Muscular Atrophy page for current treatments, recruiting trials, and community resources.
How Apitegromab works
Apitegromab: fully human IgG4 monoclonal antibody that binds promyostatin and latent myostatin, blocking myostatin activation and releasing the body's brake on muscle growth. Our full Apitegromab profile covers how it works, side effects in plain language, and its trial history.
Where Spinal Muscular Atrophy treatment stands today
Read our full Spinal Muscular Atrophy treatment summary
SMA now has two separate kinds of treatment, and the distinction matters when you are weighing trials. SMN-targeted therapies protect motor neurons and include Spinraza, Evrysdi, the one-time gene therapy Zolgensma, given by IV infusion to children under 2, and Itvisma (onasemnogene abeparvovec-brve), a one-time gene therapy injected into the spinal fluid (intrathecal) that the FDA approved in November 2025 for patients 2 years and older.
Muscle-targeted therapy is newer: apitegromab (Isembyld) was approved in September 2026 as an add-on for patients 2 and older who are already on Spinraza or Evrysdi, making it the first drug aimed at the muscle rather than the nerve. Research continues on improved delivery, new splicing approaches, and further muscle-directed agents.
Early diagnosis through newborn screening, where available, is critical for outcomes, and Cure SMA and patient registries help families compare options. Your pediatric or adult neuromuscular specialist can discuss which approved therapies and which open trials match your SMA type and current function.
Ask your team to record a baseline motor function score before starting anything new, since that number is what any later decision to continue or stop will be measured against.
The Spinal Muscular Atrophy page has every treatment and trial →Meanwhile, 64 Spinal Muscular Atrophy studies are open or about to open
The FDA's decision does not end research on Spinal Muscular Atrophy. The most recently updated:
You'll hear about future FDA decisions and new recruiting trials for Spinal Muscular Atrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
Has the FDA decided on Apitegromab?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: Scholar Rock press release
What was Apitegromab approved for?
The FDA approved Scholar Rock's BLA for Apitegromab in Spinal muscular atrophy (SMA).
What to know: Approved 19 days ahead of its September 30th action date as the first muscle-targeted treatment for SMA. The label requires patients to already be on an SMN2-targeted therapy, making it an add-on rather than a replacement.
How it works: Fully human IgG4 monoclonal antibody that binds promyostatin and latent myostatin, blocking myostatin activation and releasing the body's brake on muscle growth.
More: the Apitegromab drug page explains it in plain language.
Is there already an FDA-approved treatment for Spinal Muscular Atrophy?
Yes. Trial Friend's drug list includes 5 FDA-approved drugs for Spinal Muscular Atrophy.
Approved: Spinraza (nusinersen), Zolgensma (onasemnogene abeparvovec), Evrysdi (risdiplam), Itvisma (onasemnogene abeparvovec-brve), Isembyld (apitegromab).
Check: the Spinal Muscular Atrophy page also searches FDA drug labels for approved treatments.
What did the Apitegromab trials show?
Approval rested on SAPPHIRE (NCT05156320), a Phase 3 randomized, double-blind, placebo-controlled trial of 188 patients with 5q SMA aged 2 to 21 across 9 countries, published in The Lancet Neurology in 2025. Every participant was already receiving nusinersen or risdiplam, and every participant was nonambulatory at baseline with a Type 2 or Type 3 diagnosis.
More: the Apitegromab drug page has the full trial history and sources.
What are the side effects of Apitegromab?
Fractures are the one risk that carries a dedicated warning in the label, occurring in 9% of patients on the recommended dose versus 2% on placebo, and they can happen with or without a fall. Femur fractures occurred in 3 treated patients in the main trial.
Most common: upper respiratory infections, vomiting, cough, viral infections, headache, stomach flu.
More: the Apitegromab drug page has the label's warnings in full.
How much will Apitegromab cost?
Trial Friend does not list a price for Apitegromab. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Drugmaker help: Scholar Rock Supports.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Apitegromab decision?
The FDA approved Apitegromab for Spinal muscular atrophy (SMA) on September 11, 2026.
Next steps: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
Where this outcome comes from
The outcome on this page comes from Scholar Rock press release. This page rechecks against our calendar, which is re-verified daily.